What is SpeeDx?
SpeeDx is a diagnostics company specializing in the development of innovative molecular assays for the detection of viral and bacterial infections, alongside markers for antibiotic resistance. Their product portfolio includes multiplex assays designed for research use, targeting areas such as sexually transmitted infections and respiratory pathogens. Established in 2009, SpeeDx operates globally with a presence in Austin, London, and Sydney, serving laboratories and research institutions. The company leverages advanced qPCR technology and automation to enhance laboratory workflows and boost productivity.
How much funding has SpeeDx raised?
SpeeDx has raised a total of $10M across 1 funding round:
Private Equity
$10M
Private Equity (2019): $10M with participation from Northpond Ventures
Key Investors in SpeeDx
Northpond Ventures
Northpond Ventures is a venture capital firm that typically invests in companies at the forefront of scientific innovation, particularly in the life sciences and technology sectors. Their investment in SpeeDx suggests a focus on diagnostic technologies with significant market potential.
What's next for SpeeDx?
The recent major strategic investment into SpeeDx signals a strong validation of the company's technological advancements and market strategy. This capital is likely to fuel further research and development, potentially expanding their assay capabilities and global reach. With a focus on enhancing laboratory efficiency and diagnostic accuracy, SpeeDx is well-positioned to capitalize on the growing demand for sophisticated molecular diagnostics, particularly in areas of infectious disease and antimicrobial resistance. Future growth may involve scaling production, entering new geographical markets, or forging strategic partnerships to broaden the application of their innovative solutions.
See full SpeeDx company page
